11 Results for "

GSK3-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "GSK3-IN-2" in MCE Product Catalog:

Cat. No.: HY-148329
CAS No.: 380450-97-5
Purity:  99.87%
Target:  

GSK-3

Research Areas:  

Metabolic Disease

GSK3-IN-2 (compound 8) is a potent GSK3 inhibitor .
loading...
    loading...
Cat. No.: HY-172171
CAS No.: 3068378-38-8
Target:  

GSK-3 β-catenin Wnt

Research Areas:  

Neurological Disease

GSK3β-IN-2 (Compound S01) is the inhibitor for GSK3β with an IC50 of 0.35 nM. GSK3β-IN-2 activates Wnt/β-catenin signaling pathway, promotes neurogenesis and neurite growth. GSK3β-IN-2 inhibits Aβ-induced tau hyperphosphorylation at Ser396, reduces the formation of neurofibrillary tangles. GSK3β-IN-2 ameliorates Alzheimer's Disease in zebrafish model .
loading...
    loading...
Cat. No.: HY-154852
CAS No.: 2227279-83-4
Purity:  98.77%
Target:  

GSK-3 CDK

Research Areas:  

Neurological Disease

GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .
loading...
    loading...
Cat. No.: HY-174398
Target:  

GSK-3 HDAC Tau Protein

Research Areas:  

Neurological Disease

GSK-3β/HDAC-IN-2 is a potent inhibitor of GSK-3β (IC50 = 0.04 μM), HDAC2 (IC50 = 1.05 μM, Ki = 0.070 μM) and HDAC6 (IC50 = 1.52 μM, Ki = 0.017 μM). GSK-3β/HDAC-IN-2 inhibits HDAC2 and HDAC6 activities and blocks tau hyperphosphorylation. GSK-3β/HDAC-IN-2 exerts neuroprotective effects and shows no significant toxicity. GSK-3β/HDAC-IN-2 can be used in the research of Alzheimer's disease.
loading...
    loading...
Cat. No.: HY-N12625
CAS No.: 1364123-68-1
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC50s of 1.1, 0.95, >10, >10 and >10 μM, respectively .
loading...
    loading...
Cat. No.: HY-111932
CAS No.: 244021-67-8
Target:  

CDK GSK-3

Research Areas:  

Cancer

Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .
loading...
    loading...
Cat. No.: HY-P1114
CAS No.: 186901-17-7
Target:  

GSK-3

Research Areas:  

Neurological Disease

2B-(SP) is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) is readily phosphorylated by both the α and β isoforms of GSK-3 .
loading...
    loading...
Cat. No.: HY-P1114A
Target:  

GSK-3

Research Areas:  

Cancer

2B-(SP) TFA is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) TFA is readily phosphorylated by both the α and β isoforms of GSK-3 .
loading...
    loading...
Cat. No.: HY-184741
Target:  

GSK-3 VEGFR Akt MEK ERK

Research Areas:  

Cancer

GSK-3β/VEGFR2-IN-1 is an orally active dual inhibitor of GSK-3β (IC50 = 325 nM) and VEGFR2 (IC50 = 78 nM). GSK-3β/VEGFR2-IN-1 suppresses the phosphorylation of VEGFR2, AKT, MEK and ERK, inhibits human tongue squamous cell carcinoma cells migration and suppresses formation of HUVECs, exhibits low toxicity towards other cancer cells and normal cells, demonstrates significant antitumor efficacy in a CAL27 xenograft mouse model. GSK-3β/VEGFR2-IN-1 can be used for the study of tongue squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-186130
CAS No.: 3110929-05-7
Target:  

Calpain

Research Areas:  

Neurological Disease

CAST-calpain-2 stabilizer-1 is a blood-brain barrier permeable stabilizer of CAST-calpain-2 interaction. CAST-calpain-2 stabilizer-1 shows no activity against GSK3. CAST-calpain-2 stabilizer-1 can be used in the research of Huntington's disease and tauopathies .
loading...
    loading...
Cat. No.: HY-183584
ARN25699 is a kinase inhibitor with an IC50 of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies .
loading...
    loading...
  • 1